Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
53
Active, not recruiting, industry sponsors, Neurology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting120
- Completed845
53 trials
Showing 1 to 25, recently updated first.
- Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's DiseaseActive, not recruiting
Lexeo TherapeuticsIndustry
NCT05400330 · 10 participants · Start May 8, 2023 · Primary completion Nov 2028
Drug: LX1001 · For: Alzheimer Disease
Sites: Orlando, Florida; Durham, North Carolina
- Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)Active, not recruiting
UniQure Biopharma B.V.Industry
NCT06100276 · 20 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 30, 2030
Drug: AMT-162 · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Irvine, California; San Francisco, California · 12 sites in all
- A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04995523 · 212 participants · Start Sep 14, 2021 · Primary completion Jun 1, 2028
Drug: AZD2936 · For: Non-Small-Cell Lung Carcinoma
Sites: Chicago, Illinois; Rochester, Minnesota; Fairfax, Virginia · 40 sites in all
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07667322 · 75 participants (planned) · Start Dec 17, 2024 · Primary completion Sep 1, 2026
Drug: Ocrelizumab Co-formulated With rHuPH20 · For: Multiple Sclerosis
Sites: Carlsbad, California; Maitland, Florida; Tampa, Florida · 12 sites in all
- A Phase 1b Study of BHV-7000 in Participants With Inherited ErythromelalgiaActive, not recruiting
Biohaven Therapeutics Ltd.Industry
NCT07262268 · 5 participants (planned) · Start Jan 15, 2026 · Primary completion Nov 2027
Drug: BHV-7000; Placebo · For: Familial Erythromelalgia
Sites: New Haven, Connecticut
- VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseaseActive, not recruiting
Voyager TherapeuticsIndustry
NCT06874621 · 52 participants (planned) · Start Mar 3, 2025 · Primary completion Oct 13, 2026
Drug: VY7523; Placebo Comparator · For: Alzheimer's Disease (AD)
Sites: Los Angeles, California; Orange, California; San Francisco, California · 23 sites in all
- Regulatory T Cells for Amyotrophic Lateral SclerosisActive, not recruiting
Cellenkos, Inc.Industry
NCT05695521 · 66 participants (planned) · Start Apr 3, 2023 · Primary completion May 2027
Drug: CK0803 · For: Amyotrophic Lateral Sclerosis
Sites: New York, New York; Houston, Texas · 3 sites in all
- A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple SclerosisActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07008378 · 60 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 31, 2032
Drug: P-CD19CD20-ALLO1 Cells; Cyclophosphamide and 1 more · For: Multiple Sclerosis
Sites: La Jolla, California; St Louis, Missouri; New Brunswick, New Jersey · 4 sites in all
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Active, not recruiting
Prevail TherapeuticsIndustry
NCT04127578 · 32 participants (planned) · Start Jan 3, 2020 · Primary completion Aug 31, 2031
Drug: LY3884961; Methylprednisolone and 1 more · For: Parkinson Disease
Sites: Scottsdale, Arizona; Murrieta, California; Englewood, Colorado · 15 sites in all
- The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's DiseaseActive, not recruiting
XellSmart Therapeutics (Shanghai) Co., Ltd.Industry
NCT07080775 · 39 participants · Start Aug 5, 2025 · Primary completion Jul 2027
Drug: human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection · For: Parkinson's Disease
Sites: Beijing, China
- Study in Subjects With Mild-to-Moderate Alzheimer's DementiaActive, not recruiting
Alzamend Neuro, Inc.Industry
NCT05834296 · 30 participants (planned) · Start Jul 5, 2023 · Primary completion Mar 3, 2028
Drug: ALZN002 (autologous DCs pulsed with E22W mutant peptide).; Placebo · For: Alzheimer Disease
Sites: Doral, Florida
- BXQ-350 in Newly Diagnosed Metastatic Colorectal CarcinomaPivotal-lookingActive, not recruiting
Bexion Pharmaceuticals, Inc.Industry
NCT05322590 · 195 participants (planned) · Start Jan 9, 2023 · Primary completion Nov 2026
Drug: BXQ-350 · For: Metastatic Colorectal Carcinoma; Neuropathy
Sites: Birmingham, Alabama; Orange, California; San Francisco, California · 12 sites in all
- Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease ParticipantsActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05469360 · 38 participants · Start Feb 23, 2023 · Primary completion Jul 30, 2026
Drug: NIO752; NIO752 and 5 more · For: Alzheimer Disease; Mild Cognitive Impairment
Sites: Kuopio, Finland; Turku, Finland; Lille, France · 10 sites in all
- A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05704361 · 119 participants (planned) · Start Aug 11, 2021 · Primary completion Jul 8, 2027
Drug: RO7121932 IV; RO7121932 SC · For: Multiple Sclerosis
Sites: Stanford, California; New Haven, Connecticut; Brussels, Belgium · 26 sites in all
- Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's DiseasePivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04639050 · 241 participants · Start Mar 15, 2021 · Primary completion Jul 31, 2027
Drug: RO7126209; Placebo · For: Alzheimers Disease
Sites: Atlantis, Florida; Clermont, Florida; Lady Lake, Florida · 37 sites in all
- To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy VolunteersActive, not recruiting
Everfront Biotech Co., Ltd.Industry
NCT03651349 · 56 participants (planned) · Start Feb 1, 2021 · Primary completion Dec 31, 2027
Drug: HK-001; Placebo control · For: Amyotrophic Lateral Sclerosis
Sites: Hualien City, Taiwan
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)Active, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07234942 · 6 participants · Start Jan 27, 2026 · Primary completion Mar 31, 2027
Drug: RO7812653; Placebo · For: Alzheimer's Disease
Sites: Toronto, Canada; Montreal, Canada; Amsterdam, Netherlands · 12 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06675864 · 28 participants (planned) · Start Dec 12, 2024 · Primary completion Jun 14, 2030
Drug: rapcabtagene autoleucel (YTB323) · For: Progressive Multiple Sclerosis
Sites: Darlinghurst, Australia; Melbourne, Australia; Québec, Canada · 18 sites in all
- Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06049212 · 30 participants (planned) · Start Oct 26, 2023 · Primary completion Dec 31, 2027
Drug: Sacituzumab tirumotecan; Pembrolizumab and 1 more · For: Non-small Cell Lung Cancer; Solid Tumors; Programmed Cell Death-1 (PD1, PD-1) and 2 more
Sites: Nagoya, Japan; Kashiwa, Japan; Matsuyama, Japan · 7 sites in all
- An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple SclerosisActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06617793 · 28 participants (planned) · Start Feb 24, 2025 · Primary completion Aug 7, 2030
Drug: rapcabtagene autoleucel (YTB323) · For: Relapsing Multiple Sclerosis
Sites: Darlinghurst, Australia; Melbourne, Australia; Montpellier, France · 18 sites in all
- A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory NeuroblastomaActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04106219 · 71 participants (planned) · Start Jun 11, 2020 · Primary completion Apr 13, 2022
Drug: LY3295668 Erbumine; Topotecan and 1 more · For: Neuroblastoma
Sites: San Francisco, California; Aurora, Colorado; Chicago, Illinois · 17 sites in all
- Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual PatientActive, not recruiting
Vanda PharmaceuticalsIndustry
NCT07223632 · 1 participants · Start May 13, 2025 · Primary completion Mar 2027
Drug: VCA-894A · For: Charcot Marie Tooth Disease (CMT); Neuromuscular Diseases (NMD)
Sites: Madison, Wisconsin
- Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05853367 · 95 participants · Start Jul 6, 2023 · Primary completion Jun 24, 2028
Drug: MK-0472; Pembrolizumab and 1 more · For: Metastatic Solid Tumors; Advanced Solid Tumors
Sites: Chicago, Illinois; Louisville, Kentucky; Hackensack, New Jersey · 25 sites in all
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
NCT06220201 · 120 participants (planned) · Start Mar 28, 2024 · Primary completion Jul 15, 2027
Drug: CC-97540; Fludarabine and 1 more · For: Multiple Sclerosis; Myasthenia Gravis
Sites: Birmingham, Alabama; Irvine, California; Aurora, Colorado · 34 sites in all
- A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic EncephalopathyActive, not recruiting
Praxis Precision MedicinesIndustry
NCT05737784 · 60 participants (planned) · Start Apr 13, 2023 · Primary completion Apr 1, 2026
Drug: PRAX-222 - Initial Dose; PRAX-222 - Initial Ascending Doses and 2 more · For: SCN2A-DEE; Epilepsy
Sites: Memphis, Tennessee; Porto Alegre, Brazil; São Paulo, Brazil
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.